Kartos Therapeutics

Home | Kartos Theraputics

Employees
11–50
Business Model
B2B
Total Funding
$90.0M
Last Round
$90.0M Series BJan 2020
Rounds
1

About

Clinical-stage biopharmaceutical company developing navtemadlin, an investigational MDM2 inhibitor for oncology.

Tech & App Stack

Tech & App Stack is available on paid plans

Upgrade to Silver or higher to reveal the full technology and app stack for any company.

View pricing

Sign up to view funding chart

Create a free account to see funding visualizations and detailed round data.

Create Free Account

Funding History

Series BSeries BJan 2020
$90.0M

Investors

Sign up to view investors

Create a free account to see which investors have funded this company.

Create Free Account

Similar Companies